Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1998 1
2000 1
2001 1
2002 5
2003 10
2004 9
2005 16
2006 16
2007 10
2008 14
2009 21
2010 18
2011 28
2012 28
2013 38
2014 43
2015 29
2016 32
2017 32
2018 39
2019 29
2020 32
2021 30
2022 22
2023 21
2024 40
2025 57
2026 27

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

569 results

Results by year

Filters applied: . Clear all
Page 1
Non-HDL-cholesterol in dyslipidemia: Review of the state-of-the-art literature and outlook.
Raja V, Aguiar C, Alsayed N, Chibber YS, ElBadawi H, Ezhov M, Hermans MP, Pandey RC, Ray KK, Tokgözoglu L, Zambon A, Berrou JP, Farnier M. Raja V, et al. Atherosclerosis. 2023 Oct;383:117312. doi: 10.1016/j.atherosclerosis.2023.117312. Epub 2023 Sep 30. Atherosclerosis. 2023. PMID: 37826864 Free article. Review.
In addition, large follow-up studies have reported that individuals with higher baseline non-HDL-C at a younger age (<45 years) were more prone to adverse CVD events at an older age, suggesting a predictive ability of non-HDL-C over the long term. . …
In addition, large follow-up studies have reported that individuals with higher baseline non-HDL-C at a younger age (<45 ye …
Intensive early and sustained lowering of non-high-density lipoprotein cholesterol after myocardial infarction and prognosis: the SWEDEHEART registry.
Schubert J, Leosdottir M, Lindahl B, Westerbergh J, Melhus H, Modica A, Cater N, Brinck J, Ray KK, Hagström E. Schubert J, et al. Eur Heart J. 2024 Oct 14;45(39):4204-4215. doi: 10.1093/eurheartj/ehae576. Eur Heart J. 2024. PMID: 39217499 Free PMC article.
BACKGROUND AND AIMS: Non-HDL-C provides an estimate of lipid-associated risk and is a secondary treatment target after myocardial infarction (MI). ...Outcomes were major adverse cardiovascular event (MACE: death, MI, and ischaemic stroke), death, and non-fatal MI. …
BACKGROUND AND AIMS: Non-HDL-C provides an estimate of lipid-associated risk and is a secondary treatment target after myocard …
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.
Wharton S, Aronne LJ, Stefanski A, Alfaris NF, Ciudin A, Yokote K, Halpern B, Shukla AP, Zhou C, Macpherson L, Allen SE, Ahmad NN, Klise SR; ATTAIN-1 Trial Investigators. Wharton S, et al. N Engl J Med. 2025 Nov 6;393(18):1796-1806. doi: 10.1056/NEJMoa2511774. Epub 2025 Sep 16. N Engl J Med. 2025. PMID: 40960239 Clinical Trial.
Waist circumference, systolic blood pressure, triglyceride levels, and non-HDL cholesterol levels significantly improved with orforglipron treatment as compared with placebo. ...
Waist circumference, systolic blood pressure, triglyceride levels, and non-HDL cholesterol levels significantly improve …
Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.
Ballantyne CM, Gellis L, Tardif JC, Banka P, Navar AM, Asprusten EA, Scott R, Stroes ESG, Froman S, Mendizabal G, Wang F, Catapano AL. Ballantyne CM, et al. JAMA. 2026 Jan 13;335(2):129-139. doi: 10.1001/jama.2025.20620. JAMA. 2026. PMID: 41206969 Free PMC article. Clinical Trial.
The secondary outcomes included the mean percentage change in LDL-C level at week 52, the mean percentage change at week 24 in levels of non-high-density lipoprotein cholesterol (non-HDL-C) and apolipoprotein B, and the median percentage change at week 24 in …
The secondary outcomes included the mean percentage change in LDL-C level at week 52, the mean percentage change at week 24 in levels of non …
Safety and efficacy of statin therapy.
Adhyaru BB, Jacobson TA. Adhyaru BB, et al. Nat Rev Cardiol. 2018 Dec;15(12):757-769. doi: 10.1038/s41569-018-0098-5. Nat Rev Cardiol. 2018. PMID: 30375494 Review.
The 2013 ACC/AHA guidelines on blood cholesterol management were a major shift in the delineation of the main patient groups that could benefit from statin therapy and emphasized the use of higher-intensity statin therapies. In 2016, an expert consensus panel from the ACC …
The 2013 ACC/AHA guidelines on blood cholesterol management were a major shift in the delineation of the main patient groups that cou …
Comparative effectiveness of statins on non-high density lipoprotein cholesterol in people with diabetes and at risk of cardiovascular disease: systematic review and network meta-analysis.
Hodkinson A, Tsimpida D, Kontopantelis E, Rutter MK, Mamas MA, Panagioti M. Hodkinson A, et al. BMJ. 2022 Mar 24;376:e067731. doi: 10.1136/bmj-2021-067731. BMJ. 2022. PMID: 35331984 Free PMC article.
OBJECTIVE: To compare the efficacy of different statin treatments by intensity on levels of non-high density lipoprotein cholesterol (non-HDL-C) for the prevention of cardiovascular disease in people with diabetes. ...The primary outcome was changes in levels …
OBJECTIVE: To compare the efficacy of different statin treatments by intensity on levels of non-high density lipoprotein cholesterol …
The association between non-HDL cholesterol and high-grade pancreatic neuroendocrine neoplasms.
Zhou H, Zhu Y, Qin B, Liu Y, Wang Z, Guo C, Wang J, Chen X. Zhou H, et al. Endocrine. 2024 Nov;86(2):584-591. doi: 10.1007/s12020-024-03910-4. Epub 2024 Jun 6. Endocrine. 2024. PMID: 38844608
Few studies have shown the effect of non-HDL-c in malignant tumors. The present study aimed to identify the association between non-HDL-c and high-grade pancreatic neuroendocrine neoplasms (PNENs). ...Non-HDL-c was calculated as total …
Few studies have shown the effect of non-HDL-c in malignant tumors. The present study aimed to identify the association betwee …
Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia.
Rosenson RS, Gaudet D, Hegele RA, Ballantyne CM, Nicholls SJ, Lucas KJ, San Martin J, Zhou R, Muhsin M, Chang T, Hellawell J, Watts GF; ARCHES-2 Trial Team. Rosenson RS, et al. N Engl J Med. 2024 Sep 12;391(10):913-925. doi: 10.1056/NEJMoa2404147. Epub 2024 May 29. N Engl J Med. 2024. PMID: 38809174 Clinical Trial.
ANGPTL3 loss-of-function carriers have lower levels of triglycerides, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and non-HDL cholesterol and a lower risk of atherosclerotic cardiovascular disease than …
ANGPTL3 loss-of-function carriers have lower levels of triglycerides, low-density lipoprotein (LDL) cholesterol, high-density lipopro …
Rationale and design of the effect of evolocumab in patients at high cardiovascular risk without prior myocardial infarction or stroke (VESALIUS-CV) trial.
Bohula EA, Marston NA, Ruzza A, Murphy SA, De Ferrari GM, Diaz R, Leiter LA, Elliott-Davey M, Wang H, Bhatia AK, Giugliano RP, Sabatine MS. Bohula EA, et al. Am Heart J. 2024 Mar;269:179-190. doi: 10.1016/j.ahj.2023.12.004. Epub 2023 Dec 29. Am Heart J. 2024. PMID: 38160917
BACKGROUND: The reduction of low-density lipoprotein cholesterol (LDL-C) with evolocumab, a fully human monoclonal antibody inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9i), reduces the risk of major adverse cardiovascular events in patients with establi …
BACKGROUND: The reduction of low-density lipoprotein cholesterol (LDL-C) with evolocumab, a fully human monoclonal antibody inhibitor …
Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk.
Marston NA, Bergmark BA, Alexander VJ, Prohaska TA, Kang YM, Moura FA, Zimerman A, Waldman E, Weinland J, Murphy SA, Goodrich EL, Zhang S, Xia S, Li D, Goldberg AC, Goudev A, Badimon L, Kiss RG, Vrablik M, Gaudet D, Moulin P, Stroes ESG, Banach M, Cohen H, Blom D, Charng MJ, Nordestgaard BG, Nicholls SJ, Tsimikas S, Giugliano RP, Sabatine MS; CORE-TIMI 72a and CORE2-TIMI 72b Investigators. Marston NA, et al. N Engl J Med. 2026 Jan 29;394(5):429-441. doi: 10.1056/NEJMoa2512761. Epub 2025 Nov 8. N Engl J Med. 2026. PMID: 41211918 Clinical Trial.
Secondary lipid outcomes included the percent change in the triglyceride level at 12 months and in apolipoprotein C-III, remnant cholesterol, and non-high-density lipoprotein (non-HDL) cholesterol at 6 months and 12 months. ...Decreases in the levels o …
Secondary lipid outcomes included the percent change in the triglyceride level at 12 months and in apolipoprotein C-III, remnant choleste …
569 results